Virusliterature

HBV mutation literature information.

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.

PMID: 10760047 2000 Journal of viral hepatitis

Abstract: As expected, lamivudine was much less ( approximately 200-fold) effective at inhibiting replication of the M550V mutant virus than the wild-type virus.

Abstract: Several nucleoside analogues (penciclovir, lobucavir, dioxalane guanine [DXG], 1-beta-2,6-diaminopurine dioxalane [DAPD], L-FMAU, lamivudine) and acyclic nucleoside phosphonate analogues (adefovir, tenofovir) that are in clinical use, in clinical trials or under preclinical development for the treatment of hepatitis B virus (HBV) infections, were evaluated for their inhibitory effect on the replication of a la- mivudine-resistant HBV variant containing the methionine --> valine substitution (M550V) in the polymerase nucleoside-binding domain.

Abstract: The antiviral activity was determined in the tetracycline-responsive HepAD38 and HepAD79 cells, which are stably transfected with either a cDNA copy of the wild-ty

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

PMID: 10762559 2000 The Journal of infectious diseases

Abstract: No mutation in the YMDD motif was observed, whereas an L528M mutation was clearly selected by famciclovir treatment in 2 patients, as well as 14 novel mutations in 7 patients.

A frequent, naturally occurring mutation (P130T) of human hepatitis B virus core antigen is compensatory for immature secretion phenotype of another frequent variant (I97L).

PMID: 10775637 2000 Journal of virology

Abstract: Our current study demonstrates that this abnormality can be efficiently offset by another frequent core mutation, P130T.

[Hepatitis B virus gene mutations in the sera of three patients with coexisting hepatitis B surface antigen and anti-surface antibody].

PMID: 10804824 2000 Rinsho byori. The Japanese journal of clinical pathology

Abstract: Case 1 possessed a point mutation, T to C at nucleotide position 1753, in the region overlapping the coding region of the X gene and the CCAAT/enhancer binding protein(C/EBP) binding region within the core promoter region.

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.

PMID: 10827158 2000 Hepatology (Baltimore, Md.)

Abstract: Of the 23 patients included, 13 harbored either one or a mixture of the two common YMDD-motif mutants (methionine 552-to-isoleucine [M552I] and leucine 528-to-methionine/methionine 552-to-valine [L528M/M552V]) throughout the course, whereas in the remaining 10 patients, distinct mutants became dominant over the original mutants to cause continuing chronic hepatitis.

Abstract: Of them, 3 developed an alanine 529-to-threonine (A529T) mutant, 6 developed a leucine 528-to-methionine/methionine 552-to-isoleucine (L528M

Detection of hepatitis B virus surface antigen mutants in paraffin-embedded hepatocellular carcinoma tissues.

PMID: 10949955 2000 Virus genes

1Abstract: Mutations on the ""a"" determinant (Thr126Ser, Gly145Arg, a double mutant Thr126Ser/Gln129Asn, Met 133Leu and Thr140Ile) were identified in 5 samples while the wild type sequence was found in 2 others."

In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy - a clinical note.

PMID: 10996115 2000 Journal of clinical virology

Abstract: Nineteen weeks later, the virus exhibited additional resistance-associated mutations (L528M and I552V).

Abstract: Significant genotypic resistance was detectable after 68 weeks, indicated by a substitution of isoleucine for methionine at residue 552 (M552I).

Hepatitis B virus X gene variability in French-born patients with chronic hepatitis and hepatocellular carcinoma.

PMID: 11002246 2000 Journal of medical virology

1Abstract: The changes K130M and V131I, considered as ""hot spot mutations,"" were found in strains of HCC patients carrying an ayw subtype of the HBV genome but not in the ones of chronically infected patients."

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.

PMID: 11020004 2000 Journal of hepatology

Abstract: Breakthrough viremia was not associated with the single L528M mutation.

Abstract: CONCLUSION: Our observations show that the virus populations conferring resistance to lamivudine can evolve from single to double mutations at amino acid 552 and 528 of the HBV polymerase, and that M552I/ L528M or M552V/L528M seem to be the predominant mutations arising during long-term antiviral therapy with lamivudine.

Abstract: In the majority of lamivudine-resistant isolates the mutations have been reported to occur within the YMDD motif of the viral polymerase, either as a single mutation M552I or as M552V concomitant with

PMID: 11050059 2000 Hepatology (Baltimore, Md.)

Abstract: Determination of viral genotype, precore mutants, and polymerase gene mutants (L528M, M552V, M552I) was performed using the research version of Lipa-HBV.

Browser Board

Co-occurred Entities

Filtrator